2.Godoy P, et al. Measles epidemiology in Catalonia (Spain): implications for a regional vaccination programme. International Journal of Epidemiology 1999; 28: 558–562.
3.Moss WJ. Measles control and the prospect of eradication. Current Topics in Microbiology and Immunology 2009; 330: 173–189.
4.Centers for Disease Control and Prevention.Progress in global measles control and mortality reduction, 2000–2007. Morbidity and Mortality Weekly Report 2008; 57: 1303–1306.
5.Lee MS, et al. Epidemiology of measles in Taiwan: dynamics of transmission and timeliness of reporting during an epidemic in 1988–9. Epidemiology and Infection 1995; 114: 345–359.
6.Lee MS, et al. Seroepidemiology and evaluation of passive surveillance during 1988–1989 measles outbreak in Taiwan. International Journal of Epidemiology 1992; 21: 1165–1174.
7.Liu CC, Lei HY, Chiang YP. Seroepidemiology of measles in southern Taiwan: two years after implementation of the measles elimination program. Journal of Formosan Medical Association 1996; 95: 37–40.
8.Cheng WY, et al. Molecular evolution of measles viruses circulated in Taiwan 1992–2008. Virology Journal 2009; 6: 219.
9.Lin HJ, et al. Measles cluster in Tainan area, early 2009. Taiwan Epidemiology Bulletin 2010; 26: 12–25.
10.Lee NY, et al. Modified measles in a healthcare worker after return from travel. Infection Control and Hospital Epidemiology 2008; 29: 380–381.
11.Nagano H, et al. Epidemiological and molecular studies of measles at different clusters in hokkaido district, Japan, 2007. Japanese Journal of Infectious Diseases 2009; 62: 209–211.
12.Mendelson GM, et al. Nosocomial transmission of measles to healthcare workers. Time for a national screening and immunization policy for NHS staff? Journal of Hospital Infection 2000; 44: 154–155.
13.Biellik RJ, Clemens CJ. Strategies for minimizing nosocomial measles. Transmission. Bulletin of the World Health Organization 1997; 75: 367–375.
14.Atkinson WL, et al. Transmission of measles in medical settings – United States, 1985–1989. American Journal of Medicine 1991; 91: 320S–324S.
15.Davis RM, et al. Transmission of measles in medical settings: 1980 through 1984. Journal of American Medical Association 1986; 255: 1295–1298.
16.Lee SS, et al. Nosocomial transmission of undetected, imported measles in Taiwan, 2008. Infection Control and Hospital Epidemiology 2009; 30: 1026–1028.
17.Weigle KA, Murphy MD, Brunell PA. Enzyme-linked immunosorbent assay for evaluation of immunity to measles virus. Journal of Clinical Microbiology 1984; 19: 376–379.
18.Chen SC, et al. Modelling vaccination programmes against measles in Taiwan. Epidemiology and Infection 2007; 135: 775–786.
19.Watson JC, et al. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports 1998; 47: 1–57.
20.Lee MS, et al. Measles seroepidemiology and decay rate of vaccine-induced measles IgG titers in Taiwan, 1995–1997. Vaccine 2001; 19: 4644–4651.
21.McDonald LC, et al. SARS in healthcare facilities, Toronto and Taiwan. Emerging Infectious Diseases 2004; 10: 777–781.
22.Yalcin SS, Kanra G, Pehlivan T. Outbreak of measles in medical students and determination of immune status to measles-mumps-rubella viruses. International Journal of Adolescent Medicine and Health 2006; 18: 615–622.
23.Wicker S, et al. Seroprevalence of vaccine preventable and blood transmissible viral infections (measles, mumps, rubella, polio, HBV, HCV and HIV) in medical students. Medical Microbiology and Immunology 2007; 196: 145–150.
24.Williams CJ, et al. Low measles, mumps and rubella (MMR) vaccine uptake in hospital healthcare worker contacts following suspected mumps infection. Journal of Hospital Infection 2010; 76: 91–92.
25.Tischer A, Gerike E. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella. Vaccine 2000; 18: 1382–1392.
26.Wang ET, et al. Emergency response and policy consideration on measles epidemics. Taiwan Epidemiology Bulletin 2007; 23: 308–26.
27.Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. New England Journal of Medicine 2007; 357: 1903–1915.
28.Dine MS, et al. Persistence of vaccine-induced antibody to measles 26–33 years after vaccination. Journal of Infectious Diseases 2004; 189: S123–S130.
29.Davidkin I, et al. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. Journal of Infectious Diseases 2008; 197: 950–956.
30.Hatakeyama S, et al. Prevalence of measles, rubella, mumps, and varicella antibodies among healthcare workers in Japan. Infection Control and Hospital Epidemiology 2004; 25: 591–594.
31.Fedeli U, Zanetti C, Saia B. Susceptibility of healthcare workers to measles, mumps, rubella and varicella. Journal of Hospital Infection 2002; 51: 133–135.
32.Almuneef MA, et al. Seroprevalence survey of varicella, measles, rubella, and hepatitis A and B viruses in a multinational healthcare workforce in Saudi Arabia. Infection Control and Hospital Epidemiology 2006; 27: 1178–1183.
33.Williamson D, et al. Seroprevalence of measles antibodies among high-risk healthcare workers in Auckland, New Zealand: additional justification for assumption of age-determined immunity based on local data. Infection Control and Hospital Epidemiology 2010; 31: 1082–1084.